Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. [electronic resource]
Producer: 20080108Description: 281-8 p. digitalISSN:- 1097-0215
- Adaptor Proteins, Signal Transducing -- metabolism
- Antineoplastic Agents -- pharmacology
- Apoptosis
- B-Cell CLL-Lymphoma 10 Protein
- Carboplatin -- pharmacology
- Cell Line, Tumor
- Cisplatin -- pharmacology
- Drug Resistance, Neoplasm
- Erythropoietin -- pharmacology
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Ovarian Neoplasms -- metabolism
- Paclitaxel -- pharmacology
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Recombinant Proteins -- chemistry
- Signal Transduction
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.